An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
2022-06-29
عنوان الدراسة
An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
داعم الدراسة
Synageva
دواء الدراسة
Sebelipase alfa (SBC-102)
رقم بروتوكول الدراسة
LAL-CL03
حالة الدراسة
Completed
موقع الدراسة
KFSH & RC-R
مرحلة الدراسة
2
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.